SAN DIEGO, CA / ACCESSWIRE / January 6, 2015 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma"), (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective non-prescription over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today that it will be presenting at the OneMedForum held in San Francisco, CA from January 12 - 13, 2015 at the San Francisco Marriot Marquis.
Event: OneMedForum
Location: San Francisco Marriot Marquis
Date: Tuesday, January 12, 2015
Time: 1:40 PM (PT)
Management will deliver a presentation and provide an overview of Innovus Pharma's business operations including 2014 milestone accomplishments and revenue growth, and will discuss it's 2015 projected growth plan and upcoming milestones. The Company has five commercial products and has signed partnerships to sell certain of the Company's products in 28 countries. The Company's products include:
1. Zestra(R) clinically proven to increase desire and arousal in women;
2. EjectDelay(R) indicated for the treatment of premature ejaculation;
3. Sensum+(TM) to increase penile sensitivity;
4. Vesele(R) to boost sexual and cognitive health; and
5. Zestra Glide(R), the only high viscosity, low osmolality water based lubricant.
In addition to the presentation, management will be available for one-on-one meetings.
To arrange a meeting with management, please contact Lynnette Dillen, Executive Vice President and Chief Financial Officer at ir@innovuspharma.com.
More information on Innovus Pharma can be found on www.innovuspharma.com; www.zestra.com, www.ejectdelay.com, www.sensumplus.com, www.myvesele.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra(R) clinically proven to increase arousal and desire, EjectDelay(R) for premature ejaculation, and has a total of five marketed products in this space, including Sensum+(TM) (for sales outside the U.S. only), Zestra Glide(R) and Vesele(R) for increasing blood flow to enhance sexual and mental health.
For more information, go to www.innovuspharma.com.
Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra(R), to successfully commercialize such products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Innovus Pharma Contact:
Lynnette Dillen
Innovus Pharmaceuticals
ir@innovuspharma.com
T: 858-964-5123
SOURCE: Innovus Pharmaceuticals, Inc.